Hims & Hers Health (NYSE:HIMS) Downgraded by Zacks Research to “Strong Sell”

Hims & Hers Health (NYSE:HIMS) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports.

Several other research analysts have also weighed in on the stock. Citigroup lifted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a report on Tuesday, May 12th. Evercore set a $24.00 price target on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Finally, Bank of America dropped their price objective on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 26th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average price target of $28.70.

Hims & Hers Health Trading Up 6.8%

NYSE HIMS opened at $29.02 on Monday. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The stock has a 50-day simple moving average of $24.93 and a 200 day simple moving average of $26.91. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $6.72 billion, a PE ratio of -322.40, a P/E/G ratio of 50.98 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business posted $0.20 EPS. Research analysts forecast that Hims & Hers Health will post 0.04 EPS for the current year.

Insider Activity at Hims & Hers Health

In related news, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David B. Wells bought 48,400 shares of the stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have sold 212,807 shares of company stock valued at $5,473,644. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of the company. Farallon Capital Management LLC increased its position in shares of Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the last quarter. BIT Capital GmbH boosted its position in Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after purchasing an additional 938,728 shares during the last quarter. SG Americas Securities LLC grew its stake in Hims & Hers Health by 25.6% in the fourth quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after purchasing an additional 75,679 shares in the last quarter. Vanguard Group Inc. grew its stake in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares in the last quarter. Finally, CI Investments Inc. increased its position in shares of Hims & Hers Health by 6,659.7% during the 3rd quarter. CI Investments Inc. now owns 206,510 shares of the company’s stock worth $11,713,000 after purchasing an additional 203,455 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.